RT Journal Article
SR Electronic
T1 Application of RNA-sequencing based predictive model for endometrial WOI in patients with recurrent implantation failure: a prospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.26.24307954
DO 10.1101/2024.05.26.24307954
A1 He, Aihua
A1 Yang, Tianli
A1 Lu, Sijia
A1 Zou, Yangyun
A1 Wan, Cheng
A1 Zhao, Jing
A1 Liu, Nenghui
A1 Liu, Donge
A1 Li, Yumei
A1 Wang, Yonggang
A1 Xu, Bin
A1 Hao, Jie
A1 Xie, Shi
A1 Fu, Jing
A1 Li, Hui
A1 Wu, Hong
A1 Zhang, Qiong
A1 Li, Yanping
YR 2024
UL http://medrxiv.org/content/early/2024/05/27/2024.05.26.24307954.abstract
AB Background Accurate prediction for endometrial window of implantation (WOI) would maximize the effectiveness of assisted reproductive technology. Previously, we have established a predictive model for endometrial WOI (rsERT) by three-time points sampling from the same patient at 48-hour intervals during one menstrual cycle. However, it is imperative to build a modified rsERT by single time point sampling in order to prevent multiple sampling and collateral harm.Methods A two-phase study was conducted. In the first phase, patients with successful clinical pregnancy after personalized embryo transfer (pET) guided by three-time points rsERT were recruited. Endometrial tissues obtained from single time point were used for the modified rsERT establishment. In the second phase, recurrent implantation failure (RIF) patients were recruited and assigned to experimental group underwent pET guided by modified rsERT’ or control group underwent conventional ET. Pregnant outcomes were recorded and analyzed.Results The modified rsERT was established using 91 eligible participants and could provide hour-based predictive result of endometrial WOI with an average accuracy of 94.51% with sensitivity and specificity being 92.73% and 96.27% using 10-fold CV. 176 RIF patients were recruited in the second phase (experimental group: n=88; control group: n=88). 40 of 88 (45.45%) patients showed WOI displacement, and 5.00% (2/40) of them were with advanced WOI, and the remaining 95.00% (38/40) with delayed WOI. The β-hCG positive rate, intrauterine pregnancy rate (IPR) and implantation rate (IR) of the experimental group were significantly improved (β-hCG positive rate: 67.05% vs. 39.77%, P=0.000; IPR: 61.36% vs. 31.82%, P=0.000; IR: 42.86% vs. 24.66%, P=0.001). While, pregnancy outcomes were not significantly different using different endometrial preparation protocols (β-hCG positive rate: 42.86% vs. 35.90%, P=0.508; IPR: 38.78% vs. 23.08%, P=0.116; IR: 30.12% vs. 17.46%, P=0.085).Conclusions The modified rsERT allowed WOI prediction using a single time point endometrial biopsy and pregnancy outcomes were significantly improved. This could provide an enhanced endometrial receptivity test as an alternative, requiring only a single time point sampling for RIF patients.Funding Research grants from Hunan Provincial Natural Science Foundation General Program (2023JJ30823) and Postdoctoral Fellowship Program of CPSF (GZC20233157).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR-DDD-17013375Funding StatementThis study was supported by the Hunan Provincial Natural Science Foundation General Program (2023JJ30823) and Postdoctoral Fellowship Program of CPSF (GZC20233157).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Reproductive Medicine Ethics Committee of Xiangya Hospital, Central South University (CSU) (No. 2017002) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.ARTassisted reproductive technologyAMHanti-Mullerian hormoneAFCantral follicle countBMIbody mass indexCIconfidence intervalDEGsdifferentially expressed genesERendometrial receptivityERAendometrial receptivity arrayETembryo transferE2estradiolFSHfollicle-stimulating hormoneFETfrozen embryo transferHRThormone replacement therapyIPRintrauterine pregnancy rateIRimplantation rateIQRinterquartile rangeIVFin vitro fertilizationLHluteinizing hormonePprogesteronepETpersonalized embryo transferPSMpropensity score matchingPGSpre-implantation genetic screeningPGDpre-implantation genetic diagnosisRIFrecurrent implantation failurersERTRNA-sequencing based endometrial receptivity testSDstandard deviationTtestosteroneWOIwindow of implantationβ-hCGβ-human chorionic gonadotropin.